WO2009122447A1 - Composé semi-synthétique de sesquiterpène-lactone-parthénine utile de par sa cytotoxicité contre les lignées de cellules cancéreuses, et anticancéreux - Google Patents

Composé semi-synthétique de sesquiterpène-lactone-parthénine utile de par sa cytotoxicité contre les lignées de cellules cancéreuses, et anticancéreux Download PDF

Info

Publication number
WO2009122447A1
WO2009122447A1 PCT/IN2009/000218 IN2009000218W WO2009122447A1 WO 2009122447 A1 WO2009122447 A1 WO 2009122447A1 IN 2009000218 W IN2009000218 W IN 2009000218W WO 2009122447 A1 WO2009122447 A1 WO 2009122447A1
Authority
WO
WIPO (PCT)
Prior art keywords
hydroxy
cancer
azuleno
furan
dione
Prior art date
Application number
PCT/IN2009/000218
Other languages
English (en)
Inventor
Ghulam Nabi Qazi
Subhash Chandra Taneja
Jaswant Singh
Ajit Kumar Saxena
Vijay Kumar Sethi
Bhahwal Ali Shah
Ajay Kumar
Samar Singh Andotra
Fayaz Malik
Shanmugavel Muthiah
Satyam Kumar Agrawal
Original Assignee
Council Of Scientific & Industrial Research
Department Of Biotechnology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Council Of Scientific & Industrial Research, Department Of Biotechnology filed Critical Council Of Scientific & Industrial Research
Publication of WO2009122447A1 publication Critical patent/WO2009122447A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/93—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems condensed with a ring other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Definitions

  • the pre ⁇ nt invention relates to semi-synthetic sesquiterpene lactone parthenin compound of generjl formula 1, useful for cytotoxicity against cancer cell lines and anticancer activity.
  • the present invention relates to semi-synthetic sesquiterpene lactone parthenin compound of general formula 1, useful for anticancer and anti-tumor activity and cytotoxicity against human cancer cell lines at a therapeutically effective dosage.
  • the present invention reUjtes to the field of chemotherapeutics particularly use of novel semiTsynthetic analogues of a sesquiterpene lactone, parthenin, a constituent of Parthenium horsferophprus as cytotoxic agent.
  • the invention particularly relates to structure modification of a natu/al product i.e. a sesquiterpene lactone commonly known as parthenin with a view to imppye ajrid modify the bioactivity, particularly its cytotoxicity and hence anticancer activity.
  • the semi-synthetic molecules of this invention are new as they have not been either prepared or reported for cytotoxic/anticancer activity.
  • the semi-synthetic molecules along with the cytotoxic/anticancer activity disclosed in the present invention are novel and not known in art of subject matter Of the present invention. These novel analogues when screened in vitro displayed projnounced cytotoxic activity at low concentrations in various human cancer cell lines.
  • Parthenium hysterophorus commonly known as congress weed is an aggressive weed of the America including Caribbean. It is somewhat unattractive member of the composite (Asteraceae) family. In the last 100 years, it has found its way to Africa, Australia and Asia.
  • Parthenium causes severe human and animal health problems. It is responsible for allergic contact dermatitis in human and toxic to catties. Allergic contact dermatitis may be caused by the major sesquiterpene lactone parthenin or other constituents which are found in the trichomes of leaf and stem [Herz,W. J. Am. Chem. Soc. 26, 5011 (1959)]. Probably it is also responsible for the toxic effect in livestock. It has also been found to cause respiratory allergies.
  • Parthenium is having some industrial uses as reported in the literatures [Sastry, Tenjarla, CS. and K.Y. Kavathekar, (1990) Publications and Informations Directorate, CSIR, New Delhi].
  • hysterophon ⁇ is described as a weed to be used as tonic, febrifuge, and emmenagogue.
  • Root decoction is useful in dysentery [Singh, U., Wadhwani, A.M. and John, B.M. (1996), Dictionary of economic plants in India ICAR, New Delhi].
  • Parthenium is also reported to display activity against hepatic ameobiasis [Sharma, G.L.
  • Parthenin the major sesquiterpene lactones from Parthenium hysterophorus also possesses q , ⁇ -unsaturated -Y- lactone moiety which is considered to be an essential requirement for lactones to possess such activity [S.M.Kupchan et al. J.Med. Chem. ⁇ 2, 1147 (1971)].
  • the anti-tumor effects of the major sesquiterpene lactones of Parthenium hysterophorus, parthenin have been studied both in vivo and in vitro by Mew et al in 1982. In vivo studies showed that molecule could either cure mice or increase their survival time after intraperitoneal or subcutaneous injection with tumour cells.
  • Sesquiterpene lactones isolated from some natural sources have been shown to possess activity against tumor growth and inflammatory conditions [I. Hall et al., "Anti-inflammatory activity of sesquiterpene lactones and related compounds, " J. Pharm. ScI, vol. 68, pp. 537-542 (1979); I. Hall et al., "Mode of action of sesquiterpene aactones as anti-Inflammatory agents," J. Pharm. Sci., vol. 69, pp. 537-543 (1980)].
  • Sesquiterpene lactone helenalin and related compounds have reportedly displayed antitumor activity (K. Lee, "Antitumor Agents. 32. Synthesis and Antitumor Activity of Cyplopentenone perivatives Related to Helenalin," J. Med. Chem., vol. 21, pp. 819-822 (1978); K. Lee et al., "Cytotoxicity of Sesquiterpene Lactones," Cancer Research, vol. 3 l,pp 164? «- 1654 (1971)]; Other related work includes [J. Cassady, "Potential antitumor agents. Synthesis, reactivity, and cytotoxicity of alpha. -methylene carbonyl compounds, " J. Med Chem., vol.
  • Another object of the present invention is to provide a method for the preparation of the said semi-synthetic sesquiterpene lactone parthenin compound of general formula 1.
  • Yet another object of the present invention is to provide a pharmaceutical composition
  • a pharmaceutical composition comprising the said semi-synthetic sesquiterpene lactone parthenin compound of general formula 1, optionally along with pharmaceutically acceptable additives and carriers.
  • Stjll another object of the present invention is to provide the use of the compounds or pharmaceutical composition thereof for the anticancer activity and cytotoxicity against human cancer cell lines.
  • the present invention provides a sesquiterpene lactone parthenin compound of general formula 1, obtained semi-synthetically from plant weed Parthenium hysterophorus.
  • the semi-synthetic compounds show cytotoxicity on a panel of human cancer cell lines at low concentrations, thus can be effectively used in cancer therapy.
  • the present invention provides a semi-synthetic sesquiterpene lactone of compound of general formula 1
  • R 2 is H or an alkyl group having C2-C10 alkyl chain or hydroxyethoxyl radical
  • R 3 is selected from the group comprising hydrogen, halogen, hydroxyl radicals
  • R 4 is selected from the group comprising hydrogen, halogen, hydroxyl, hydroxyethoxyl and N- imidazolyl radicals wherein halogen is chloro or bromo radicals
  • R 5 is selected from the group comprising hydrogen, hydroxyl, acetoxyl and propyloxyl radicals
  • R 7 is an alkyl radical having C2-C8 alkyl chain
  • R is H or an alkyl radical having C2-C 10 alkyl chain or an aromatic group.
  • the aromatic radical is selected from furan, thiophene and substituted benzene.
  • substituted benzene is 4- substituted benzene or 3,4-disubstituted benzene or 3,4,5-trisubstituted benzene, wherein substituent pn the benzene ring is selected from the group comprising chloro, bromo, hydroxy, methpxy, methylenedioxy, nitro, amino, and amino acyl group.
  • alkyl radical is C1-C8 alkyl chain.
  • halogen is selected from chloro-, bromo- and iodo- radicals.
  • a pharmaceutical composition comprising an effective amount of semi-synthetic sesquiterpene lactone compound of general formula l(i) or l(ii) optionally along with pharmaceutically acceptable carriers or additives, useful for anticancer activity against cancer cell lines.
  • the pharmaceutically acceptable carriers or additives used are selected form Gum Acacia (1.0 to 2.0%), DMSO ⁇ 0.3 to 1.0% ⁇ and / or Normal Saline.
  • the said composition induces programmed cell death (apoptosis) as means of cancer cell killing, a desired molecular target of anti-cancer drugs.
  • the present invention provides a method for treating cancer in a subject, wherein the said method comprising the steps of administering the effective amount of semisynthetic sesquiterpene lactone compound of general formula 1 as claimed in claim 1 or pharmaceutical composition thereof.
  • composition of the present invention is useful for the treatment of cancer selected from the group comprising alimentary or gastrointestinal tract cancer, breast cancer, brain cancer, bladder cancer, bone cancer, colon cancer, kidney cancer, leukemia, liver cancer, lymphoma, lung cancer, muscle cancer, ovarian cancer, prostate cancer and skin cancer.
  • the subject is mammal including human.
  • the route of administering the said composition is selected from oral, nasal, intra-peritoneal and intra-venous.
  • composition used is selected from the group comprising liquid, tablet, capsule, powder, gel, granules.
  • the additives used are selected from the group of its pharmaceutically acceptable salts, hydrates, solvates, crystals and the like.
  • the cancer is selected from the group comprising alimentary or gastrointestinal tract cancer, breast cancer, brain cancer, bladder cancer, bone cancer, colon cancer, kidney cancer, leukemia, liver cancer, lymphoma, lung cancer, muscle cancer, ovarian cancer, prostate cancer and skin cancer.
  • the therapeutically effective dose of the said composition is in the range of 10-lOOmg/ml.
  • the said composition induces programmed cell death (apoptosis) as means of cancer cell killing, a desired molecular target of anti-cancer drugs.
  • the cancer cells lines are from breast, bone, bladder, colon, liver, skin, lymphoma, leukemia, kidney, lung, muscle, ovarian and prostate cancer.
  • the said composition induces programmed cell death (apoptosis) by means of pro-oxidant effect inhibiting cell proliferation and caspase-3 induction.
  • the killing of cancer cell lines is up to 98% when the concentration of the said composition is ranging between IxIO "6 M - 5x10 "5 M.
  • a method for treating cancer in a subject comprises the steps of administering the effective amount of semi-synthetic sesquiterpene lactone compound of general formula 1 or pharmaceutical composition thereof.
  • the subject is mammal including human.
  • the route of administering the said composition is selected from oral, nasal, intra-peritoneal and intra-venous.
  • the form in which the said composition used is selected from the group comprising liquid, tablet, capsule, powder, gel, granules.
  • the present invention provides a process for preparation of semi-synthetic sesquiterpene lactone compound of general formula 1 comprising the steps: (i) reacting the parthenin with an aldehyde selected from a group consisting of formaldehyde, acetaldehyde, propionaldehyde, butyraldehyde, valeraldehyde, heptanaldehyde, benzaldehyde, 4-chlorobenzaldehyde, 4-methoxy benzaldehyde, piperonal and cinnamaldehyde in presence of l,8-diazabicyclo[5,4,0]undec-7-ene
  • an aldehyde selected from a group consisting of formaldehyde, acetaldehyde, propionaldehyde, butyraldehyde, valeraldehyde, heptanaldehyde, benzaldehyde, 4-chlorobenzaldehy
  • Scheme 12 represents synthesis of compound of formula l(i), where, OH, OCH 3 ,
  • Table 1 shows in vitro toxicity against some human cancer cell lines of compounds of formula 1
  • Table 2 shows in vitro toxicity against some other human cancer cell lines of compounds of formula 1
  • the present invention is aimed to develop a potent cytotoxic/anti-cancer drug which is active at low concentration and poses minimum side effects.
  • the semi-synthetic compounds of the present invention have neither been reported in the chemical literature nor have been used for the cytotoxic activity.
  • the synthesis of the novel compounds have been accomplished through the combination of various chemical steps known in the art of synthesis though not for the purpose of synthesizing of the compounds of formulae 1 as described above.
  • a structural formulae 1 comprising the chemical structures as shown in the drawings or a pharmaceutically acceptable composition
  • R is H or an alkyl radical having C2-C10 alkyl chain or a aromatic moiety wherein the aromatic group is selected from a substituted benzene and where substituted benzene is a 4-substituted benzene or a 3,4- disubstituted benzene or 3,4,5-trisubstituted benzene, where substituent on benzene ring are selected from chloro, bromo, hydroxy, methoxy, methylenedioxy, nitro, amino, and amino acyl groups;
  • Ri is H or a radical selected from hydoxymethyl, acetoxymethyl grpups ;
  • R 2 is H or an alkyl group having C2-C10 alkyl chain pr hydroxyethoxyl radical; where R 3 is selected from hydrogen, hal
  • the present invention comprises the compounds prepared via different reactions that may incl ⁇ de Baylis Hillman reaction, nucleophilic addition across ⁇ , ⁇ -unsaturated double bond, etc.
  • the method comprises the reaction of Parthenin with trimethyl amine in presence of primary alcohols such as ethanol, methanol, ethlyleglycol and the like were used effect 1,4-addition on ⁇ , ⁇ -unsaturated pentanone or ⁇ -butyrolactone ring system to produce desired compounds of formula 1.
  • primary alcohols such as ethanol, methanol, ethlyleglycol and the like were used effect 1,4-addition on ⁇ , ⁇ -unsaturated pentanone or ⁇ -butyrolactone ring system to produce desired compounds of formula 1.
  • the cells at sub- confluent stage were harvested from flask by treatment with trypsin (0.05% trypsin in PBS containing 0.02% EDTA) and suspended in complete growth medium. Cells with cell viability of more than 97% by trypan blue exclusion technique were used for determination of cytotoxicity.
  • N ⁇ hrpmosuccinimide (NBS, lOOmg, 0.56mmol) was added to a solution of natural Parthenin
  • the human cancer cell lines were obtained either from National Center for Cell Science, Pune or National Cancer Institute, Fredrick, Md., USA. Cells were grown in tissue culture flasks in complete growth medium (RPMI- 1640 medium with 2mM glutamine, lOO ⁇ g/ml streptomycin, pH 7.4, sterilized by filtration and supplemented with 10% sterilized fetal calf serum and 100 units/ml penicillin before use) at 37 0 C in an atmosphere of 5% CO 2 and 90% relative humidity in a carbon dioxide incubator. The cells at sub-confluent stage were harvested from flask by treatment with trypsin (0.05% trypsin in PBS containing 0.02% EDTA) and suspended in complete growth medium. Cells with cell viability of more than 97% by trypan blue exclusion technique were used for determination of cytotoxicity.
  • complete growth medium RPMI- 1640 medium with 2mM glutamine, lOO ⁇ g/ml streptomycin, pH 7.4, sterilized by filtration and supplemented with 10%
  • Test material was dissolved in DMSO (dimethyl sulphoxide) to obtain a stock solution of 2x10 "2 M.
  • the stock solution was serially diluted with complete growth medium containing 5P ⁇ g/ml of gentamycin to obtain working test solutions of required concentrations.
  • the suspension of human cancer cell lines of required cell density in complete growth medium was prepared and cell suspension (100 ⁇ l/well) of each cell line was added to wells of 96- well tissue culture plate. Suitable blanks and controls were also included. The plates were incubated for 24hrs in a carbon dioxide incubator.
  • the working test solutions of different concentrations were added after incubation. The plates were further incubated for 48-hrs after addition of test material.
  • the cell growth was stopped by gently layering of 50 ⁇ l of TCA (50% trichloroacetic acid) on top of the medium in all the wells.
  • TCA 50% trichloroacetic acid
  • the plates were incubated at 4°C for one hour to fix the cells attached to bottom of the wells. Liquids of all the wells were gently pipetted out and discarded. The plates were washed five times with distilled water to remove TCA, growth medium, low molecular weight metabolites, serum proteins etc. The plates were air dried.
  • Cell growth was measured by staining with sulforhodamine B dye (SRB). The SRB solution (100 ⁇ l, 0.4% in 1% acetic acid) was added to each well and the plates were incubated at room temperature for 30 minutes.
  • SRB sulforhodamine B dye
  • the unbound SRB was quickly removed by washing the wells five times with 1% acetic acid solution and plates were air dried. Tris buffer (100 ⁇ l, 0.01 M, pH 10.4) was added to all the wells and plates were gently stirred for 5 minutes on a mechanical stirrer. The optical density was recorded on ELISA reader at 540 nra. The cell growth in presence of test material was calculated in term of percentage of growth inhibition.
  • the Parthenin compounds produced DNA fragmentation in HL- 60 cells indicating that some of the compounds kill cells by programmed cell death exemplified by agarose-gel DNA fragmentation pattern of about 180 base pairs ladder.
  • l(ii) where,
  • the cells were grown in culture and incubated with indicated concentrations of the compounds for 4 hr.
  • ROS reactive oxygen species
  • the level of intracellular ROS (peroxides) was determined by using 2 ⁇ T- dichlorofluoresceindiacetate.
  • the non-fluorescent compound DCFH-DA has the ability to permeate cells freely where it is deesterified to DCFH, which is further oxidized to DCF that remains entrapped inside the cells.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

La présente invention concerne un composé semi-synthétique de sesquiterpène-lactone-parthénine représenté par la formule générale (I), et utile de par sa cytotoxicité contre les lignées de cellules cancéreuses et de par son activité anticancéreuse. Un autre aspect de l'invention concerne une composition pharmaceutique entrant dans la composition dudit composé. L'invention concerne également une dose thérapeutique de ladite composition et un procédé permettant de traiter le cancer d'un sujet par administration d'une quantité suffisante de ce composé de sesquiterpène-lactone-parthénine, ou d'une composition pharmaceutique à base de ce composé, par voie orale, nasale, intra-péritonéale, ou intraveineuse. Cette composition s'utilise sous forme de liquide, de comprimés, de gélules, de poudre, de gel ou de granulés.
PCT/IN2009/000218 2008-03-31 2009-03-31 Composé semi-synthétique de sesquiterpène-lactone-parthénine utile de par sa cytotoxicité contre les lignées de cellules cancéreuses, et anticancéreux WO2009122447A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN840/DEL/2008 2008-03-31
IN840DE2008 2008-03-31

Publications (1)

Publication Number Publication Date
WO2009122447A1 true WO2009122447A1 (fr) 2009-10-08

Family

ID=40791219

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2009/000218 WO2009122447A1 (fr) 2008-03-31 2009-03-31 Composé semi-synthétique de sesquiterpène-lactone-parthénine utile de par sa cytotoxicité contre les lignées de cellules cancéreuses, et anticancéreux

Country Status (1)

Country Link
WO (1) WO2009122447A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101421140B1 (ko) 2010-04-23 2014-07-18 난카이 유니버시티 메킬리아 락톤 유도체, 그 약제학적 조성물 및 그 제조방법과 용도
CN104016952A (zh) * 2013-02-28 2014-09-03 东北林业大学 一种新的倍半萜活性成分及其制备方法与应用
WO2015188169A1 (fr) * 2014-06-07 2015-12-10 Academia Sinica Nouveaux dérivés sesquiterpène et leur utilisation dans le traitement de l'inflammation et du cancer
JP2018526457A (ja) * 2015-09-11 2018-09-13 ファフル エル−ディン エル−サーウィ，モハメド 薬用のアンブローシア属植物抽出物
CN113387915A (zh) * 2021-06-29 2021-09-14 海南师范大学 一种桉烷型倍半萜内酯类tbb衍生物及其制备方法、用途
CN114805382A (zh) * 2022-05-18 2022-07-29 中国科学院兰州化学物理研究所 一种倍半萜色酮类化合物及其分离和在制备抗胰腺癌药物中的应用

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
ABDEL HALIM, O. B. ET AL: "Metabolism of parthenin by Beauveria bassiana ATCC 7159", PHARMAZIE , 62(3), 226-230 CODEN: PHARAT; ISSN: 0031-7144, 2007, XP009119124 *
BHAT, U. G. ET AL: "Alumina-catalyzed reactions of parthenin and its derivatives", INDIAN JOURNAL OF CHEMISTRY, SECTION B: ORGANIC CHEMISTRY INCLUDING MEDICINAL CHEMISTRY , 27B(11), 989-93 CODEN: IJSBDB; ISSN: 0376-4699, 1988, XP009119102 *
DAS ET AL: "Acetylated pseudoguaianolides from Parthenium hysterophorus and their cytotoxic activity", PHYTOCHEMISTRY, PERGAMON PRESS, GB, vol. 68, no. 15, 1 August 2007 (2007-08-01), pages 2029 - 2034, XP022440942, ISSN: 0031-9422 *
DATABASE CA [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; CAGGIANO, THOMAS J.: "Nickel Boride", XP002537092, retrieved from STN Database accession no. 2008:994428 *
E-EROS ENCYCLOPEDIA OF REAGENTS FOR ORGANIC SYNTHESIS , NO PP. GIVEN PUBLISHER: JOHN WILEY & SONS, LTD., CHICHESTER, UK. CODEN: 69KUHI URL: HTTP://WWW3.INTERSCIENCE.WILEY.COM/CGI-BIN/MRWHOME/104554785/HOME, 2001 *
HOOPER, M. ET AL: "Antimalarial activity of parthenin and its derivatives", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY , 25(9), 717-23 CODEN: EJMCA5; ISSN: 0223-5234, 1990, XP002537089 *
MEW D ET AL: "Anti-tumour effects of the sesquiterpene lactone parthenin", PLANTA MEDICA, THIEME, STUTTGART, DE, vol. 45, no. 1, 1 January 1982 (1982-01-01), pages 23 - 27, XP009119026, ISSN: 0032-0943 *
RAMESH, C. ET AL: "Analogues of parthenin and their antibacterial activity", ARKIVOC (GAINESVILLE, FL, UNITED STATES) , (9), 126-132 CODEN: AGFUAR URL: HTTP://WWW.ARKAT-USA.ORG/ARK/JOURNAL/2003/CHATTERJEE/AC-953K/AC- 953K.PDF, 2003, XP009119104 *
SARMA, D. N. ET AL: "Nickel boride reductive cleavage of allylic trimethylsilyl ethers", TETRAHEDRON LETTERS , 26(3), 371-2 CODEN: TELEAY; ISSN: 0040-4039, 1985, XP002537091 *
SARMA, J. C. ET AL: "Dehalogenation of .alpha.-haloketones and vic-dibromides with nickel boride", TETRAHEDRON LETTERS , 26(38), 4657-60 CODEN: TELEAY; ISSN: 0040-4039, 1985, XP002537090 *
SETIA, RAJAT REKHA ET AL: "Photochemical modifications of parthenin and evaluation of the products as plant growth regulators", RESEARCH JOURNAL OF CHEMISTRY AND ENVIRONMENT , 8(1), 24-26 CODEN: RJCEF7; ISSN: 0972-0626, 2004, XP009119103 *
SHAH ET AL: "The formation of novel 1,3-dioxolanes: atypical Baylis-Hillman reaction of a sesquiterpene lactone parthenin", TETRAHEDRON LETTERS, ELSEVIER, AMSTERDAM, vol. 48, no. 6, 11 January 2007 (2007-01-11), pages 955 - 960, XP005827149, ISSN: 0040-4039 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101421140B1 (ko) 2010-04-23 2014-07-18 난카이 유니버시티 메킬리아 락톤 유도체, 그 약제학적 조성물 및 그 제조방법과 용도
RU2537319C2 (ru) * 2010-04-23 2015-01-10 Эксендатек Способы изготовления и назначение деривата sphaelactone и его композитные лекарства
CN104016952A (zh) * 2013-02-28 2014-09-03 东北林业大学 一种新的倍半萜活性成分及其制备方法与应用
CN104016952B (zh) * 2013-02-28 2016-05-18 东北林业大学 一种倍半萜活性成分及其制备方法与应用
WO2015188169A1 (fr) * 2014-06-07 2015-12-10 Academia Sinica Nouveaux dérivés sesquiterpène et leur utilisation dans le traitement de l'inflammation et du cancer
JP2018526457A (ja) * 2015-09-11 2018-09-13 ファフル エル−ディン エル−サーウィ，モハメド 薬用のアンブローシア属植物抽出物
JP7022064B2 (ja) 2015-09-11 2022-02-17 ファフル エル－ディン エル－サーウィ，モハメド 薬用のアンブローシア属植物抽出物
CN113387915A (zh) * 2021-06-29 2021-09-14 海南师范大学 一种桉烷型倍半萜内酯类tbb衍生物及其制备方法、用途
CN113387915B (zh) * 2021-06-29 2022-05-27 海南师范大学 一种桉烷型倍半萜内酯类tbb衍生物及其制备方法、用途
CN114805382A (zh) * 2022-05-18 2022-07-29 中国科学院兰州化学物理研究所 一种倍半萜色酮类化合物及其分离和在制备抗胰腺癌药物中的应用
CN114805382B (zh) * 2022-05-18 2023-06-27 中国科学院兰州化学物理研究所 一种倍半萜色酮类化合物及其分离和在制备抗胰腺癌药物中的应用

Similar Documents

Publication Publication Date Title
Rodrigo et al. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies
WO2009122447A1 (fr) Composé semi-synthétique de sesquiterpène-lactone-parthénine utile de par sa cytotoxicité contre les lignées de cellules cancéreuses, et anticancéreux
Pan et al. Rocaglamide, silvestrol and structurally related bioactive compounds from Aglaia species
Oliveira et al. Curcumin: a natural lead for potential new drug candidates
Kumar et al. Anticancer and immunostimulatory compounds from Andrographis paniculata
US9687469B2 (en) Agent containing flavonoid derivatives for treating cancer and inflammation
US8178727B2 (en) Bis(arylmethylidene)acetone compound, anti-cancer agent, carcinogenesis-preventive agent, inhibitor of expression of Ki-Ras, ErbB2, c-Myc and Cycline D1, β-catenin-degrading agent, and p53 expression enhancer
Thanh et al. Cytotoxic coumarins from the root of Angelica dahurica
Reddy et al. Bis-chalcone analogues as potent NO production inhibitors and as cytotoxic agents
AU2014101153A4 (en) A Group of Alkaloids, the Novel Autophagic Enhancers for Treatment of Cancers and Neurodegenerative Conditions Thereof
Chen et al. Progresses in TCM metal-based antitumour agents
Liang et al. Synthesis and in vitro and in vivo antitumour activity study of 11-hydroxyl esterified bergenin/cinnamic acid hybrids
WO2017215538A1 (fr) Dérivé de base de mannich d'acétyl-chrysine et son utilisation
An et al. Synthesis, in vitro and in vivo evaluation of new hybrids of millepachine and phenstatin as potent tubulin polymerization inhibitors
Khalilpour et al. Synthesis and Characterization of Novel Thiazolo [3, 2‐a] pyrimidine Derivatives and Evaluation of Antioxidant and Cytotoxic Activities
KR101686872B1 (ko) Tlr4에 lps와의 경쟁적 결합을 통한 항산화 및 항염증 활성을 갖는 신규 화합물 및 이의 의학적 용도
US8519163B2 (en) Anti-tumor activity of AECHL-1, novel triterpenoid isolated from Ailanthus excelsa in vitro and in vivo
Alizadeh et al. Synthesis of cytotoxic isodeoxypodophyllotoxin analogs
WO2015107119A1 (fr) Analogues de 4-azapodophyllotoxine solubles dans l'eau
JP2009274956A (ja) ニーム種子由来の悪性腫瘍治療薬
KR101457638B1 (ko) 피라졸릴나프탈레놀 유도체, 그 제법 및 그것을 포함하는 항암 조성물
Abd Razak et al. The in vivo anti-tumor effect of curcumin derivative (2 E, 6 E)-2, 6-bis (4-hydroxy-3-methoxybenzylidene) cyclohexanone (BHMC) on 4T1 breast cancer cells
US20140235877A1 (en) Compounds, methods of preparation and use thereof for treating cancer
Lodhi et al. Chemical and pharmacological evolution of some synthesized Chalcones and Hetrocyclic compounds
ADSULE et al. AJ Csian OURNALOF HEMISTRY AJ Csian OURNALOF HEMISTRY

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09729056

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09729056

Country of ref document: EP

Kind code of ref document: A1